This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While current government and commercial efforts to negotiate competitive drug prices are important, this focus represents a minor—and misplaced—implementation of medication management. It’s time that policymakers, insurers and healthcareproviders make pharmacogenomic testing a fundamental standard of care delivery.
As we approach 2025, emerging trends are reshaping how the industry engages with patients and healthcareproviders. With advancements in technology, increasing competition, and changing patient expectations, pharma marketers need to stay ahead of the curve. Patient-Centric Marketing Patients want to feel heard.
Marketing pharma has become a complex and competitive field, with companies vying for the attention of healthcareproviders (HCPs), patients, and regulators alike. With the right strategies, you can rise above the competition and drive measurable success. The good news?
HCP-Level Data This includes information about a healthcareproviders specialty, prescribing patterns, affiliations, continuing education interests, and engagement history. Verified NPI (National Provider Identifier) targeting ensures messages reach the intended physician or clinician. It’s your competitive edge.
Why It Matters: Doctors and healthcareproviders are busy. Showing up late for a meeting at a Penang private hospital or forgetting to bring a key document to a government tender discussion can harm your credibility. In a competitive field like medical sales, theyre often the difference between success and mediocrity.
When you hear that government servants in Malaysia will now be prescribed generic medications at Institut Jantung Negara (IJN), what’s your first thought? Malaysia’s Ministry of Health (MOH) recently made this decision to control rising healthcare costs. Is There Really a Big Difference? Skepticism? Will This Move Stick Around?
Depending on their area of expertise or prior involvement, healthcareproviders may receive individualized study summaries, clinical trial data, and educational materials. Early on in the process, interact with consumers and estimate the possible long-term benefits your product may provide using predictive analytics.
This can be especially important in the current global economic climate, where competition for market share is fierce, and access to new customers is critical for growth. This includes ensuring access and affordability of their products, which can positively impact their environmental social governance (ESG) score and reputation.
These companies are known for their innovation, global reach, and competitive perks. For instance, in Malaysia, success often requires understanding the dual healthcare system —balancing the needs of government hospitals, private institutions, and rural clinics. Pro Tip: Tailor your approach based on your territory.
Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape.
While they may not be directly involved in patient care, they play an important role in promoting and educating healthcareproviders about the latest treatments and technologies. Another way that pharma sales reps can contribute to society is by fostering partnerships between healthcareproviders and pharmaceutical companies.
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents. Novartis vs Greece.
Some drug products are susceptible to active pharmaceutical ingredient (API) shortages for a variety of reasons and bifurcation in the market for finished dosage form product between brand and generic drugs, for example, likewise can affect the degree of competition and product diversification in a market. About the auth or.
The rise of telehealth is altering the way healthcare is delivered, and medical sales are following suit. The proliferation of telehealth solutions has led to a significant rise in virtual sales interactions and consultations, with healthcareproviders and decision-makers embracing remote communication channels.
No surprise billing: A breakdown of the key requirements and deadlines in the No Surprises Act The No Surprises Act aims to protect patients from receiving “surprise” (or unexpected) medical bills from a healthcareprovider or facility after inadvertently receiving care from an out-of-network provider.
One of the most competitive industries in the United States is healthcare. government reveal that in 2019, spending on healthcare increased to about $3.8 But despite the success recorded in the healthcare industry, it’s often tough for many B2B healthcare marketers to get into. Statistics from the U.S.
In the competitive landscape of the pharmaceutical industry, effective marketing strategies are crucial for brand success. Pharmaceutical marketing is not just about reaching healthcare professionals and patients; it involves a complex interplay of understanding market dynamics, regulatory compliance, and leveraging digital platforms.
On the other hand, original manufacturers often face tough competition, as the market becomes flooded with alternatives. Meanwhile, generic reps focus on price and accessibility, making their pitch to healthcareproviders and patients alike. For pharma sales reps, this shift changes the conversation.
Highlight the scalability of your solution and the broader impact it could have on the healthcare industry. Leverage Non-Dilutive Funding Explore grants, accelerators, and competitions that offer non-dilutive funding options. relationships with healthcareproviders, payers, and other key stakeholders.
Highlight the scalability of your solution and the broader impact it could have on the healthcare industry. Leverage Non-Dilutive Funding Explore grants, accelerators, and competitions that offer non-dilutive funding options. relationships with healthcareproviders, payers, and other key stakeholders.
This approach not only enhances patient satisfaction but also fosters stronger relationships between pharma companies and healthcareproviders, who value the ability to offer tailored treatment options. This information is instrumental in crafting precise marketing messages that resonate with target audiences.
Recorded Session from the 2022 Consumer Experience & Digital Health Forum The Future of Healthcare’s Price Transparency is Here. Healthcareproviders and insurers are now required to publicly disclose what they pay hospitals, doctors, and other medical providers. “Is it a good or bad thing?
The Future of Healthcare’s Price Transparency is Here. Healthcareproviders and insurers are now required to publicly disclose what they pay hospitals, doctors, and other medical providers. We’re in phase 1 of healthcare’s price transparency movement – internet data dump – but what’s next?
This unique dynamic allows pharma companies to reach specific niches, such as patients with rare diseases or healthcareproviders specializing in particular fields. One of the primary obstacles is navigating the complex regulatory environment that governshealthcare communications.
One driver of rising healthcare costs is pricing, particularly the pricing of hospital services, which have been notoriously difficult to see in advance of treatment, and even more difficult to compare across providers and networks. You can learn more about Clarify’s presence at HIMSS23 here: [link].
The hiring managers and hiring process are crucial to sourcing the right candidate, as they connect healthcareproviders with products that enhance patient outcomes. These laws govern interactions with healthcareproviders and ensure transparency and ethical practices in the industry.
During the COVID-19 pandemic, pharma organizations built new digital and virtual channels to communicate with healthcareproviders (HCPs) outside of their offices. The channels alone aren’t going to produce the desired uptick in engagement without content that’s customized for each channel and personalized for each provider.
These trends are further supported by the government of Canada through investments in programmes such as the Canadian Technology Accelerator, which helps Canadian businesses focused on life sciences, digital technologies and cleantech. The Canadian digital health sector, like the global one, is growing.
Pharmaceutical companies must invest in robust data governance frameworks and collaborate with healthcareproviders, research institutions, and regulatory bodies to establish data-sharing policies and standards.
It seeks to optimize the way we establish and nurture meaningful and sustainable relationships in efforts to enhance patient experience, improve population health, reduce costs and improve the work life of healthcareproviders – ultimately leading to increased trust in and loyalty to the organization. Enhance patient experience.
Roles such as health services managers, health education specialists, physical therapists, or legal nurse consultants consulting can offer more competitive compensation packages than clinical nursing positions. They work with the patient, their families, and a healthcareprovider or physical therapist to create comprehensive care plans.
In todays rapidly evolving landscape, executives must navigate a complex mix of innovation, regulation, and competition to remain relevant. Because the way your company communicates its value to patients, healthcareproviders, and stakeholders can mean the difference between success and failure. Why does this matter?
Strong competition limits Sandoz's growth. Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition. The site employs around 250 people.
When it comes to real marketing, usually we hire nutritionists and dietitians who are doing that work and really promoting the products with healthcareproviders, mostly in the US. How do you are you dealing with competition in that market? And it's a lot of like corporate governance and reporting. And also, mothers.
Dr Sean Cahill, PhD, the associate editor of the global, peer-reviewed journal LGBT Health, says “for most young people, healthcareprovided doesn’t even go beyond that [social affirmation of gender identity], but a lot of people… are misrepresenting what gender affirming care looks like in this country”.
Table of Contents: Understanding Pharma Tariffs Impacts on Branded Drug Marketing Adjusting Digital Advertising Strategies Strategic Recommendations for Pharma Marketers Conclusion FAQs Understanding Pharma Tariffs Pharma tariffs are taxes imposed by governments on imported pharmaceutical products. FAQs What exactly are pharma tariffs?
This expansion is driven by factors such as an aging population, increasing healthcare expenditure, and a rising prevalence of chronic diseases[ ref ]. Soft skills like empathy and adaptability allow reps to stand out in a competitive market. In 2024, the market is projected to generate approximately US$1.7
But also governing from a business side; our platforms, our technologies, what is employed, trying to create a much more global digital backbone that supports all of these different use cases in the different countries. But in terms of Israel as a competitive advantage, I think data is much more than just good technology.
As we kick off 2025, those deploying AI in healthcare must be cognizant of new compliance requirements under federal and state law. International Frameworks for AI In the international arena, the European Union (EU) adopted the EU AI Act, a risk-based framework that imposes disclosure and governance obligations on developers of AI systems.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content